Literature DB >> 27618852

Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts.

Giuseppe Galati1, Ornella Leone1, Ferdinando Pasquale1, Iacopo Olivotto1, Elena Biagini1, Francesco Grigioni1, Emanuele Pilato1, Massimiliano Lorenzini1, Barbara Corti1, Alberto Foà1, Valentina Agostini1, Franco Cecchi1, Claudio Rapezzi2.   

Abstract

BACKGROUND: Although noninvasively detected myocardial fibrosis (MF) has clinical implications in hypertrophic cardiomyopathy, the extent, type, and distribution of ventricular MF have never been extensively pathologically characterized. We assessed the overall amount, apex-to-base, circumferential, epicardial-endocardial distribution, pattern, and type of MF in 30 transplanted hearts of end-stage, hypertrophic cardiomyopathy. METHODS AND
RESULTS: Visual and morphometric histological analyses at basal, midventricular, and apical levels were performed. Overall MF ranged from 23.1% to 55.9% (mean=37.3±8.4%). Prevalent types of MF were as follows: replacement in 53.3%, interstitial-perimyocyte in 13.3%, and mixed in 33.3%. Considering left ventricular base-to-apex distribution, MF was 31.9%, 43%, and 46.2% at basal, midventricular, and apical level, respectively (P<0.001). Circumferential distributions (mean percentage of MF within the section) were as follows: anterior 11.9%, anterolateral 15.8%, inferolateral 7.0%, inferior 24.3%, anteroseptal 11%, midseptal 10.7%, and posteroseptal 11.4%; circumferential distributions for anterior and inferior right ventricular walls were 3.4% and 4.5%, respectively. Epicardial-endocardial distributions were as follows: trabecular 26.1% and subendocardial 20.2%, midwall 33.4%, and subepicardial 20.3%. Main patterns identified were as follows: midwall in 33.3% of the hearts, transmural in 23.3%, midwall-subepicardial in 23.3%, and midwall-subendocardial in 20%.
CONCLUSIONS: In end-stage, hypertrophic cardiomyopathy patients undergoing transplantation, more than one-third of the left ventricular myocardium was replaced by fibrosis, mainly of replacement type. MF preferentially involved the left ventricular apex and the midwall. Inferior and anterior walls and septum were maximally involved, whereas inferolateral and right ventricular were usually spared. These observations reflect the complex pathophysiology of hypertrophic cardiomyopathy and may provide clues for the timely recognition of disease progression by imaging techniques capable of quantifying MF.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  biomarkers; hypertrophic cardiomyopathy; magnetic resonance imaging; magnetic resonance spectroscopy; sudden cardiac death

Mesh:

Year:  2016        PMID: 27618852     DOI: 10.1161/CIRCHEARTFAILURE.116.003090

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  32 in total

Review 1.  Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar.

Authors:  Javier Díez; Arantxa González; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

2.  LGE-CMR-derived texture features reflect poor prognosis in hypertrophic cardiomyopathy patients with systolic dysfunction: preliminary results.

Authors:  Sainan Cheng; Mengjie Fang; Chen Cui; Xiuyu Chen; Gang Yin; Sanjay K Prasad; Di Dong; Jie Tian; Shihua Zhao
Journal:  Eur Radiol       Date:  2018-05-04       Impact factor: 5.315

Review 3.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

4.  A machine-learning-based method to predict adverse events in patients with dilated cardiomyopathy and severely reduced ejection fractions.

Authors:  Shenglei Shu; Ziming Hong; Qinmu Peng; Xiaoyue Zhou; Tianjng Zhang; Jing Wang; Chuansheng Zheng
Journal:  Br J Radiol       Date:  2021-08-31       Impact factor: 3.039

5.  CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase.

Authors:  Sainan Cheng; Yeon Hyeon Choe; Hideki Ota; Chen Cui; Gang Yin; Minjie Lu; Lu Li; Xiuyu Chen; Sanjay K Prasad; Shihua Zhao
Journal:  Int J Cardiovasc Imaging       Date:  2017-10-25       Impact factor: 2.357

6.  Ventricular arrhythmia risk prediction in repaired Tetralogy of Fallot using personalized computational cardiac models.

Authors:  Julie K Shade; Mark J Cartoski; Plamen Nikolov; Adityo Prakosa; Ashish Doshi; Edem Binka; Laura Olivieri; Patrick M Boyle; Philip J Spevak; Natalia A Trayanova
Journal:  Heart Rhythm       Date:  2019-10-04       Impact factor: 6.343

7.  Cardiovascular magnetic resonance detects microvascular dysfunction in a mouse model of hypertrophic cardiomyopathy.

Authors:  Min-Chi Ku; Frank Kober; Yi-Ching Lai; Andreas Pohlmann; Fatimunnisa Qadri; Michael Bader; Lucie Carrier; Thoralf Niendorf
Journal:  J Cardiovasc Magn Reson       Date:  2021-05-31       Impact factor: 5.364

Review 8.  Heart failure: a story of damage, fatigue and injury?

Authors:  Prithwish Banerjee
Journal:  Open Heart       Date:  2017-10-15

9.  Routine histopathology of septal myectomy for hypertrophic obstructive cardiomyopathy in a greek cohort.

Authors:  Nikolaos S Ioakeimidis; Antonios Pitsis; Dimitrios Ntelios; Thomas Zegkos; Timotheos Kelpis; Theodora Papamitsou; Despoina Parcharidou; Georgios Efthimiadis; Soultana Meditskou
Journal:  Histol Histopathol       Date:  2021-07-30       Impact factor: 2.303

Review 10.  Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches.

Authors:  Begoña López; Susana Ravassa; María U Moreno; Gorka San José; Javier Beaumont; Arantxa González; Javier Díez
Journal:  Nat Rev Cardiol       Date:  2021-02-10       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.